Introduction and purpose  Vitamin B12 plays an important role in the process of erythropoiesis and the proper functioning of the nervous system. Its source for humans is food, in particular meat, eggs and shellfish. Cobalamin deficiency is a common problem among both geriatric and younger patients. The aim of this review is to analyze the causes of the deficit, to compare its incidence in different age groups and to try to explain potential differences between the groups. A brief description of the state knowledge Cobalamin deficiency can result from many different reasons, such as Addison-Biermer disease, damage to the ileum, use of metformin or proton pump inhibitors, insufficient supply in the diet, and less often genetic disorders. The deficiency phenomenon is more common in the elderly compared to other age groups, especially male patients with multiple comorbidities or in long-term care facilities. On the other hand, among younger people, a higher incidence is observed in the case of high body weight or height. Summary Vitamin B12 deficiency is a common clinical problem, especially among geriatric patients. Most often, cobalamin deficiency may result from reasons related to its improper absorption or deficiency in the diet, while the factors contributing to the deficiency vary depending on the age group. Elderly patients, especially those with additional risk factors, should be carefully monitored for vitamin B12 deficiency.

Introduction and objective: The purpose of this paper is to systematically review articles and new research in the context of bipolar geriatric patients. Materials and methods: PubMed searches were completed using the key terms bipolar disorder, bipolar elderly, bipolar depression, bipolar elderly treatment and review articles. In addition, references in these resources were searched. Search dates: 2010 to 2022. Description of the state of knowledge: Mental disorders in the context of the elderly concern all depressive disorders. A problem with other disorders such as bipolar disorder is also increasingly recognized. In the elderly, it is quite rare in the general cross-section of society, but it may have a higher percentage, e.g. in nursing homes and care institutions. This review article shows both the difference and the similarities in the course of this disease in older and younger patients. The most important and common aspect for both age groups is psychotherapy with parallel pharmacological treatment. The greatest difficulty in pharmacotherapy in the elderly is polypharmacy and numerous drug interactions, as well as different pharmacodynamics and pharmacokinetics of the drugs used compared to younger patients. Attention should also be paid to the differentiation of bipolar disorder from different types of dementia and other cognitive disorders. Therefore, one should strive to carefully assess the patient's need for a given treatment, establish appropriate periodic monitoring of treatment, and assess the risk of taking or not intervening. This article also aims to review new research and drugs that seem promising, while the individualized and interdisciplinary approach to a geriatric patient with BD is the most important finding of this review. Summary: Bipolar disorder in older people, compared to the younger population, should be treated pharmacologically in combination with psychotherapy. The elderly patient population requires a multidisciplinary approach due to the number of drugs used in a large number of diseases.

The purpose of this paper is a systematic review of articles and research in the context of drugs used and suicide in elderly patients. Suicide in the elderly may be much more frequent than in the younger population. In addition to factors such as mental illness, dementia, deteriorating health, or problems with adapting to old age, the impact of chronic and reliever medications in this age group should also be considered. The greatest challenge of pharmacotherapy in the elderly is polypharmacy, drug interactions, different metabolism, pharmacokinetics and pharmacodynamics of the drugs used, as well as the side effects appearing in chronic therapy. In elderly patients, strong groups of drugs such as benzodiazepines and opioids are used extensively and sometimes too often. These drugs can cause addiction and overdose. Prescribing benzodiazepines alone carries a high risk of suicide. On the other hand, opioids often lead to addiction and abuse of these drugs, which may be associated with the development of respiratory depression. According to estimates by the Centers for Disease Control and Prevention (CDC), suicide accounts for approximately 7% of all opioid overdose deaths. Therapy should be carefully selected with regard to the use of other medications, drug interactions, and possible dependence and drug abuse by patients.The use of some classes of drugs in the elderly requires increased vigilance and control in the context of depression and episodes of suicide attempts. Drugs such as B blockers, digitalis glycosides, NSAIDs, opioids, ACEIs, calcium channel blockers, corticosteroids, diuretics, levodopa, and benzodiazepines can cause symptoms of depression. Older people are more susceptible to side effects of drugs, for example because of polypharmacy and the chronicity of treatment.

Introduction and objectives. Deep brain stimulation  (DBS) is an invasive treatment method of certain neurologic and psychiatric disorders. It relies on sending external electrical stimulus to specific targets within the brain, causing change in their functioning. DBS is an approved management procedure, for instance in Parkinson’s Disease or Obsessive-compulsive disorder. Currently, studies are being conducted on the possible utilization of DBS in other disorders, especially exhibiting resistance for standard treatment. The objective of this study, is to present the state of knowledge concerning experimental usage of DBS in specific disorders. The following study is based on the review of scientific literature for the years 2000 – 2022. State of knowledge. Regarding experimental applications, DBS is being used among others in Tourette’s Syndrome, Huntington’s Disease, Depression and Alzheimer’s Disease. The review of the literature allows to gather data concerning initial patients selection, mechanism of action, potential benefits and thus far noted adverse effects. Evaluation of therapy efficacy is mostly limited, due to short observation periods and lack of unified patient qualification criteria for the operation.  Conclusion. Deep brain stimulation is a management method, in many cases acknowledged as safe and efficient. It is observed to have a beneficial impact on the disorders described in the following article. However, the approval of DBS as a conventional treatment requires improvement of many factors decisive of therapeutic success. Conduction of more randomised clinical trials in the future, may be helpful in achieving this objective.